0
Abstract: Poster Presentations |

SAFETY AND EFFICACY OF FLUTICASONE PROPIONATE PLUS SALMETEROL VIA A SINGLE DEVICE COMPARED WITH FLUTICASONE PROPIONATE ALONE IN SUBJECTS WITH ASTHMA GREATER THAN OR EQUAL TO 50 YEARS OF AGE FREE TO VIEW

Hector Ortega, MD*; William Lincourt, BS; Amanda Emmett, MS
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest


Chest. 2007;132(4_MeetingAbstracts):510a. doi:10.1378/chest.132.4_MeetingAbstracts.510a
Text Size: A A A
Published online

Abstract

PURPOSE: Most clinical studies evaluating asthma are conducted in young adults and there is limited clinical data in an older population. Therefore, the purpose of this analysis is to examine the safety and efficacy of fluticasone propionate plus salmeterol (FSC) or fluticasone propionate (FP) alone in asthmatics ≥ 50 years of age.

METHODS: A retrospective analysis from 6 twelve-week, multi-center, randomized, double-blind studies (SFCA3002, SFCA3003, SAS30001, SAS30003, SAS30004, SAS30017) examined subjects ≥ 50 years of age (range 50–82). Subjects were experiencing asthma symptoms at study enrollment. Subjects with a diagnosis of COPD, current smokers or significant co-morbid conditions were excluded from these studies. Treatments included FSC via a single device at doses of 100/50mcg or 250/50mcg twice daily (n=98) or FP at doses of 100mcg or 250mcg twice daily (n=118) via Diskus® or MDI. For analysis, FSC and FP treatment groups were pooled by dose within treatment. Mean baseline percent predicted FEV1 was 62.5% and 65.0% for the FSC and FP treatment groups, respectively. Efficacy was evaluated using AM PEF, FEV1, symptoms, and albuterol use. Safety was evaluated from adverse event reporting.

RESULTS: There were significant differences between treatments in all outcomes measured (p<0.001). Mean change from baseline AM PEF was 52.3 L/min for FSC vs 12.6 L/min for FP. Mean change in FEV1 was 0.31 L for FSC and 0.18 L for FP. Symptoms were reduced by 51% in the FSC group vs. 12% in the FP group. Supplemental albuterol use was reduced by over 65% with FSC and 23% for FP alone. There were no differences between treatment groups with regard to adverse events including cardiac events or pneumonia.

CONCLUSION: FSC provides significant clinical benefit compared with FP in patients ≥ 50 years old with asthma. The safety profiles were similar.

CLINICAL IMPLICATIONS: These results suggest that FP alone may not adequately control asthma in older patients and that salmeterol and FP (FSC) administered in a single device is more effective in this population.

DISCLOSURE: Hector Ortega, No Product/Research Disclosure Information; Employee Employee of GlaxoSmithKline

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543